covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.nuvaxovid xbb.1.5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older.the use of this vaccine should be in accordance with official recommendations.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccines - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccines - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4.2 and 5.1 in product information document).the use of this vaccine should be in accordance with official recommendations.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccines - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine
covid-19 vaccine janssen ad26.cov2.s 5x10^10 vp/0.5ml suspension for injection vial
janssen-cilag pty ltd - ad26.cov2.s, quantity: 50000000000 vp - injection, suspension - excipient ingredients: sodium chloride; polysorbate 80; sodium hydroxide; hydroxypropylbetadex; citric acid monohydrate; sodium citrate dihydrate; ethanol absolute; hydrochloric acid; water for injections - covid-19 vaccine janssen has provisional approval for the indication:,covid-19 vaccine janssen is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.,the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccines - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.spikevax bivalent original/omicron ba.1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19.spikevax bivalent original/omicron ba.4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb.1.5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older.the use of this vaccine should be in accordance with official recommendations.
covid-19 vaccine janssen (ad26.cov2-s suspension for injection
covid-19 vaccine (ad26.cov2-s [recombinant]) - suspension for injection - one dose (0.5 ml) contains: adenovirus type 26 - other viral vaccines
spikevax (elasomeran) covid-19 vaccine 0.2 mg/ml suspension for injection vial
moderna australia pty ltd - elasomeran, quantity: 0.2 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; trometamol hydrochloride; trometamol; water for injections; cholesterol; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; sodium acetate trihydrate; sucrose; distearoylphosphatidylcholine; glacial acetic acid - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment. active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.